Angiogenesis research provides foundation for drug development
Paris - Increased understanding of the basic molecular mechanisms involved in angiogenesis has suggested new targets for treating a number of dermatological and other diseases, and many compounds affecting angiogenesis are in clinical trials. However, questions remain to be answered about potential strategies for optimizing the efficacy of pro- and anti-angiogenic interventions and the safety of these novel treatments, Peter Carmeliet, Ph.D., said at the World Congress of Dermatology.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.